BenchSci Partners with Google Cloud to Close Biology's Infrastructure Gap
BenchSci, a leading provider of AI software for biopharma research and development, today announced a strategic, multi-year initiative establishing Google Cloud as the primary infrastructure platform for EMET, BenchSci's agentic research environment for preclinical drug discovery.
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. Dr. Dolsten joined BenchSci's board as a director in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development, where he could have taken a board seat at nearly any biopharma company in the world.
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.
BenchSci and Mila Partner to Advance AI for Biological Inference and Accelerate Drug Discovery
BenchSci, a leading provider of AI software for biopharma research and development, and Mila - Quebec Artificial Intelligence Institute, one of the world’s premier AI research centers, today announced a multi-year partnership to advance the use of artificial intelligence for biological inference.
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci’s ASCEND Platform
BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a three-year agreement with Sanofi to deploy and use BenchSci’s ASCEND™ platform across Sanofi’s global preclinical research organization. BenchSci’s ASCEND platform aims to significantly accelerate drug discovery efforts, enhance research efficiency, and drive innovation through the integration of cutting-edge AI and machine learning, which Sanofi will leverage through this license.
BenchSci Announces Strategic Partnership with Thermo Fisher Scientific to Create AI-powered Tools to Accelerate R&D Productivity
BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a strategic partnership with Thermo Fisher Scientific Inc., the world leader in serving science, to deliver AI-powered research tools and digital capabilities to accelerate experimental design and improve R&D productivity for scientists and researchers.
BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten
BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.
BenchSci Raises $95 Million Series D Funding to Enable Drug Discovery Innovation at Scale With its Groundbreaking AI Platform ASCEND
BenchSci, a world leader in AI solutions for preclinical life sciences research and development (R&D), today announced a $95 million (US $70 million) Series D funding round led by Generation Investment Management, with participation from existing investors iNovia Capital, TCV, Golden Ventures and F-Prime Capital. The most recent funding brings BenchSci’s total funds raised to $218 million (US $170 million).
